Glycogen synthase kinase-3 (GSK-3) inhibition induces apoptosis in leukemic cells through mitochondria-dependent pathway

Leukemia Research

Volumn 36, Issue 4, 2012, Pages 499-508

  Mirlashari, Mohammad Reza ^a   Randen, Ingrid ^a,b   Kjeldsen Kragh, Jens ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Catenin; Apoptosis; Glycogen synthase kinase 3; Leukemia; Mitochondria membrane potential

Indexed keywords

2 (3 CHLORO 4 HYDROXYANILINO) 3 (2 NITROPHENYL)MALEIMIDE; BETA CATENIN; CASPASE 8; CASPASE 8 INHIBITOR; CYCLIN B1; DEATH RECEPTOR; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GLYCOGEN SYNTHASE KINASE 3BETA; PROTEIN BCL 2; PROTEIN BCL XL;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; GROWTH INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA; LEUKEMIA CELL; LEUKEMIA CELL LINE; MEMBRANE DEPOLARIZATION; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN STABILITY; RECEPTOR BLOCKING;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SEPARATION; ENZYME INHIBITORS; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; LEUKEMIA; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICROSCOPY, ELECTRON, TRANSMISSION;

EID: 84857239448     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.11.013     Document Type: Article

References (50)

1. Jope R.S., Johnson G.V.W. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 2004, 29:95-102.
2. Frame S., Cohen P. GSK3 takes centre stage more than 20 years after its discovery. Biochem J 2001, 359:1-16.
3. Doble B.W., Woodgett J.R. GSK-3: tricks of the trade for a multitasking kinase. J Cell Sci 2003, 116:1175-1186.
4. Hedgepeth C.M., Conrad L.J., Zhang J., Huang H.C., Lee V.M., Klein P.S. Activation of the Wnt signaling pathway: a molecular mechanism for lithium action. Dev Biol 1997, 185:82-91.
5. Yost C., Torres M., Miller J.R., Huang E., Kimelman D., Moon R.T. The axis-inducing activity, stability, and subcellular distribution of beta-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3. Genes Dev 1996, 10:1443-1454.
6. Aberle H., Bauer A., Stappert J., Kispert A. Kemler R. beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J 1997, 16:3797-3804.
7. Cao Q., Lu X., Feng Y.J. Glycogen synthase kinase-3beta positively regulates the proliferation of human ovarian cancer cells. Cell Res 2006, 16:671-677.
8. Shakoori A., Mai W., Miyashita K., Yasumoto K., Takahashi Y., Ooi A., et al. Inhibition of GSK-3 beta activity attenuates proliferation of human colon cancer cells in rodents. Cancer Sci 2007, 98:1388-1393.
9. Ougolkov A.V., Fernandez-Zapico M.E., Savoy D.N., Urrutia R.A., Billadeau D.D. Glycogen synthase kinase-3beta participates in nuclear factor kappaB-mediated gene transcription and cell survival in pancreatic cancer cells. Cancer Res 2005, 65:2076-2081.
10. Zhou Y., Uddin S., Zimmerman T, Ahkang J., Ulaszek J., Wickrema A. Growth control of multiple myeloma cells through inhibition of glycogen synthase kinase-3. Leuk Lymphoma 2008, 49:1945-1953.
11. Li M., Wang X., Meintzer M.K., Laessig T., Birnbaum M.J., Heidenreich K.A. Cyclic AMP promotes neuronal survival by phosphorylation of glycogen synthase kinase 3beta. Mol Cell Biol 2000, 20:9356-9363.
12. Alao J.P., Stavropoulou A.V., Lam E.W., Coombes R.C. Role of glycogen synthase kinase 3 beta (GSK3beta) in mediating the cytotoxic effects of the histone deacetylase inhibitor trichostatin A (TSA) in MCF-7 breast cancer cells. Mol Cancer 2006, 5:40-51.
13. Urbanska K., Trojanek J., Del V.L., Eldeen M.B., Hofmann F., Garcia-Echeverria C., et al. Inhibition of IGF-I receptor in anchorage-independence attenuates GSK-3beta constitutive phosphorylation and compromises growth and survival of medulloblastoma cell lines. Oncogene 2007, 26:2308-2317.
14. Holmes T., O'Brien T.A., Knight R., Lindeman R., Shen S., Song E., et al. Glycogen synthase kinase-3beta inhibition preserves hematopoietic stem cell activity and inhibits leukemic cell growth. Stem Cells 2008, 26:1288-1297.
15. Budihardjo I., Oliver H., Lutter M., Luo X., Wang X. Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol 1999, 15:269-290.
16. Wang X. The expanding role of mitochondria in apoptosis. Genes Dev 2001, 15:2922-2933.
17. Kaufmann S.H., Earnshaw W.C. Induction of apoptosis by cancer chemotherapy. Exp Cell Res 2000, 256:42-49.
18. Cross D.A., Culbert A.A., Chalmers K.A., Facci L., Skaper S.D., Reith A.D. Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death. J Neurochem 2001, 77:94-102.
19. Coghlan M.P., Culbert A.A., Cross D.A., Corcoran S.L., Yates J.W., Pearce N.J., et al. Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem Biol 2000, 7:793-803.
20. Maity A., Hwang A., Janss A., Phillips P., McKenna W.G., Muschel R.J. Delayed cyclin B1 expression during the G2 arrest following DNA damage. Oncogene 1996, 13:1647-1657.
21. Fischer B., Coelho D., Dufour P., Bergerat J.P., Denis J.M., Gueulette J., et al. Caspase 8-mediated cleavage of the pro-apoptotic BCL-2 family member BID in p53-dependent apoptosis. Biochem Biophys Res Commun 2003, 306:516-522.
22. Fulda S., Meyer E., Friesen C., Susin S.A., Kroemer G., Debatin K.M. Cell type specific involvement of death receptor and mitochondrial pathways in drug-induced apoptosis. Oncogene 2001, 20:1063-1075.
23. May W.S., Tyler P.G., Ito T., Armstrong D.K., Qatsha K.A., Davidson N.E. Interleukin-3 and bryostatin-1 mediate hyperphosphorylation of Bcl2a in association with suppression of apoptosis. J Biol Chem 1994, 269:26865-26870.
24. Nelson W.J., Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science 2004, 303:1483-1487.
25. Ougolkov A.V., Bone N.D., Fernandez-Zapico M.E., Kay N.E., Billadeau D.D. Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor kappaB target genes and induction of apoptosis in chronic lymphocytic leukemia B cells. Blood 2007, 110:735-742.
26. Huang H.S., Liu Z.M., Cheng Y.L., Ya-Ling Involvement of glycogen synthase kinase-3b in arsenic trioxide-induced p21 expression. Toxicol Sci 2011, 121:101-109.
27. Ysebaert L., Chicanne G., Demur C., De T.F., Prade-Houdellier N., Ruidavets J.B., et al. Expression of beta-catenin by acute myeloid leukemia cells predicts enhanced clonogenic capacities and poor prognosis. Leukemia 2006, 20:1211-1216.
28. Orford K., Orford C.C., Byers S.W. Exogenous expression of beta-catenin regulates contact inhibition, anchorage-independent growth, anoikis, and radiation-induced cell cycle arrest. J Cell Biol 1999, 146:855-868.
29. Zhang Z., Hartmann H., Do V.M., Abramowski D., Sturchler-Pierrat C., Staufenbiel M., et al. Destabilization of beta-catenin by mutations in presenilin-1 potentiates neuronal apoptosis. Nature 1998, 395:698-702.
30. Kim K., Pang K.M., Evans M., Hay E.D. Overexpression of beta-catenin induces apoptosis independent of its transactivation function with LEF-1 or the involvement of major G1 cell cycle regulators. Mol Biol Cell 2000, 11:3509-3523.
31. Ersvaer E., Zhang J.Y., McCormack E., Olsnes A., Anensen N., Tan E.M., et al. Cyclin B1 is commonly expressed in the cytoplasm of primary human acute myelogenous leukemia cells and serves as a leukemia-associated antigen associated with autoantibody response in a subset of patients. Eur J Haematol 2007, 79:210-225.
32. Shimizu T., O'Connor P.M., Kohn K.W., Pommier Y. Unscheduled activation of cyclin B1/Cdc2 kinase in human promyelocytic leukemia cell line HL60 cells undergoing apoptosis induced by DNA damage. Cancer Res 1995, 55:228-231.
33. Sylte M.J., Leite F.P., Kuckleburg C.J., Inzana T.J., Czuprynski C.J. Caspase activation during Haemophilus somnus lipooligosaccharide-mediated apoptosis of bovine endothelial cells. Microb Pathog 2003, 35:285-291.
34. Ivins K.J., Thornton P.L., Rohn T.T., Cotman C.W. Neuronal apoptosis induced by beta-amyloid is mediated by caspase-8. Neurobiol Dis 1999, 6:440-449.
35. Slee E.A., Harte M.T., Kluck R.M., Wolf B.B., Casiano C.A., Newmeyer D.D., et al. Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2, -3, -6, -7 -8, and -10 in a caspase-9-dependent manner. J Cell Biol 1999, 144:281-292.
36. Wieder T., Essmann F., Prokop A., Schmelz K., Schulze-Osthoff K., Beyaert R., et al. Activation of caspase-8 in drug-induced apoptosis of B-lymphoid cells is independent of CD95/Fas receptor-ligand interaction and occurs downstream of caspase-3. Blood 2001, 97:1378-1387.
37. Ito T., Deng X., Carr B.K., May W.S. Bcl2 phosphorylation required for anti-apoptosis function. J Biol Chem 1997, 272:11671-11673.
38. Yang E., Zha J., Jockel J., Boise L.H., Thompson C.B., Korsmeyer S.J. Bad a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell 1995, 80:285-291.
39. Cheng E.H., Levine B., Boise L.H., Thompson C.B., Hardwick J.M. Bax-independent inhibition of apoptosis by Bcl-XL. Nature 1996, 379:554-556.
40. Ackler S., Xiao Y., Mitten M.J., Foster K., Oleksijew A., Refici M., et al. ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo. Mol Cancer Ther 2008, 7:3265-3274.
41. Fujimura S., Suzumiya J., Yamada Y., Kuroki M., Ono J. Downregulation of Bcl-xL and activation of caspases during retinoic acid-induced apoptosis in an adult T-cell leukemia cell line. Hematol J 2003, 4:328-335.
42. de T.A., Bettaieb A., Jean C., Laurent G., Quillet-Mary A. Role of protein kinase C zeta isoform in Fas resistance of immature myeloid KG1a leukemic cells. Blood 2001, 98:3770-3777.
43. Bailly J.D., Skladanowski A., Bettaieb A., Mansat V., Larsen A.K., Laurent G. Natural resistance of acute myeloid leukemia cell lines to mitoxantrone is associated with lack of apoptosis. Leukemia 1997, 11:1523-1532.
44. Bruno A.P., Lautier D., d'Orgeix A.T., Laurent G., Quillet-Mary A. Acute myeloblastic leukemic cells acquire cellular cytotoxicity under genotoxic stress: implication of granzyme B and perforin. Blood 2000, 96:1914-1920.
45. Wang Z., Smith K.S., Murphy M., Piloto O., Somervaille T.C., Cleary M.L. Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy. Nature 2008, 455:1205-1209.
46. Lucas F.R., Goold R.G., Gordon-Weeks P.R., Salinas P.C. Inhibition of GSK-3beta leading to the loss of phosphorylated MAP-1B is an early event in axonal remodelling induced by WNT-7a or lithium. J Cell Sci 1998, 111:1351-1361.
47. Stambolic V., Ruel L., Woodgett J.R. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol 1996, 6:1664-1668.
48. Becker R.W., Tyobeka E.M. Lithium enhances the proliferation of HL-60 promyelocytic leukemia cells. Leuk Res 1990, 14:879-884.
49. Min H.J., Koh S.S., Cho I.R., Srisuttee R., Park E.H., Jhun B.H., et al. Inhibition of GSK-3beta enhances reovirus-induced apoptosis in colon cancer cells. Int J Oncol 2009, 35:617-624.
50. Cohen Y., Chetrit A., Cohen Y., Sirota P., Modan B. Cancer morbidity in psychiatric patients: influence of lithium carbonate treatment. Med Oncol 1998, 15:32-36.